Cambridge Investment Research Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RXII Stock Details RXII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-16,065	Closed	-$22K	–	1739
2016 Q1	$22K	Sell	16,065 -3,400	-17%	-$4.66K	﹤0.01%	1582
2015 Q4	$29K	Sell	19,465 -124	-0.6%	-$185	﹤0.01%	1546
2015 Q3	$31K	Hold	19,589	–	–	﹤0.01%	1404
2015 Q2	$33K	Buy	19,589 +4,495	+30%	+$7.57K	﹤0.01%	1416
2015 Q1	$21K	Buy	15,094 +1,275	+9%	+$1.77K	﹤0.01%	1392
2014 Q4	$21K	Sell	13,819 -2,000	-13%	-$3.04K	﹤0.01%	1349
2014 Q3	$33K	Buy	+15,819	New	+$33K	﹤0.01%	1436

Other funds holding RXII

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 28.54% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Cambridge Investment Research Advisors's RXII Position: Q2 2016 in Review

Cambridge Investment Research Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q2 2016, closing a stake of 16,065 shares — an estimated $22K sold.

Cambridge Investment Research Advisors first reported a position in RXII in Q3 2014 and held it in 7 quarters. The position peaked at $33K in Q2 2015. 90 funds tracked by Wall St. Rank hold RXII as of Q2 2016.

Cambridge Investment Research Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q2 2016 after selling out during the quarter.
Cambridge Investment Research Advisors sold 16,065 GALENA BIOPHARMA INC COM shares in Q2 2016, an estimated $22K.
Cambridge Investment Research Advisors first reported a position in GALENA BIOPHARMA INC COM in Q3 2014 and held it in 7 quarters.
Cambridge Investment Research Advisors's GALENA BIOPHARMA INC COM position peaked at $33K in Q2 2015.
90 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q2 2016.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2016, filed 4 Aug 2016.